Inno Medicine Completes Nearly RMB 800 Million Series D Led by YuanBio – Funds to Drive International Multi‑Center Trials of Nanomedicine Targeted‑Delivery Pipeline

Inno Medicine announced that it has completed a Series D financing round of nearly RMB 800 million. The round was led by YuanBio Venture Capital, with follow‑on investments from a broad syndicate anchored by Beijing state‑backed funds — including the Beijing Pharmaceutical and Healthcare Industry Investment Fund and the Beijing Advanced Manufacturing and Intelligent Equipment Industry Investment Fund, both managed under the auspices of Beijing State‑owned Capital Operation and Management Co., Ltd. (BSCOMC). Proceeds will be primarily used for international multi‑center clinical trials of the company’s core pipeline products, further accelerating global clinical development and commercialization.

Financing Snapshot

Company Profile & Platform Technology

• Company: Inno Medicine, founded in 2016, an innovative enterprise dedicated to the R&D and manufacturing of novel precision targeted therapeutics.
• Core Platform: Proprietary “nanomedicine targeted delivery platform” — the technological foundation for engineering drug candidates that deliver active agents selectively to diseased tissues while limiting off‑target exposure.
• Therapeutic Focus: An innovative drug development pipeline covering multiple severe disease areas, including cardiovascular and cerebrovascular diseases and brain glioma.
• Pipeline Details: Lead candidates, development stages, and indication‑specific programs: Not disclosed in the announcement.

Strategic Rationale – Global Clinical Acceleration

• International Multi‑Center Trials: The Series D proceeds are earmarked primarily for international multi‑center clinical trials of core pipeline products — signaling a shift from China‑centric development toward globally registrational study designs.
• Commercialization Pathway: Financing will also accelerate global commercialization processes, positioning Inno Medicine to pursue both domestic and international markets for its targeted therapeutics.
• Nanomedicine in Hard‑to‑Treat Disease: Targeted nano‑delivery is particularly relevant to the company’s chosen disease areas — brain glioma, where blood–brain barrier penetration limits conventional drugs, and cardiovascular/cerebrovascular disease, where lesion‑specific delivery can improve the safety profile of potent agents. Clinical data supporting these programs: Not disclosed.

Market Impact & Outlook

• Scale of the Round: At nearly RMB 800 million, the Series D ranks among the larger late‑stage private financings in China’s nanomedicine sector this cycle, reflecting sustained investor appetite for differentiated delivery platforms despite a disciplined biotech funding environment.
• State‑Capital Endorsement: Participation by two BSCOMC‑managed Beijing industry funds, alongside market‑oriented investors such as Gaorong Ventures and Northern Light Venture Capital, blends strategic government backing with private‑market validation — a structure that often supports later‑stage regulatory and industrialization execution in China.
• Investor Confidence Signal: Existing shareholders Renhe Capital and Chunjia Capital reinvested, a continuation signal that incumbent backers retain conviction in the pipeline’s global trajectory.
• Valuation & Structure: Post‑money valuation, round structure, and cap‑table impacts: Not disclosed.

Forward‑Looking Statements
This brief contains forward‑looking statements regarding the use of Series D proceeds, initiation and outcomes of international multi‑center clinical trials, regulatory approvals, and global commercialization expectations for Inno Medicine’s pipeline. Actual results may differ materially due to risks including clinical safety and efficacy findings, trial enrollment and execution across jurisdictions, regulatory requirements, manufacturing scale‑up, and competitive dynamics in targeted nanomedicine.-Fineline Info & Tech